Objective: To evaluate visual acuity and central foveal thickness changes after bevacizumab intravitreal injection in the treatment of macular edema due to retinal vein occlusion.

Materials and Methods: In this retrospective study, 21 eyes of 21 patients who underwent bevacizumab intravitreal injection with diagnosis of macular edema due to retinal vein occlusion were examined. Three doses of intravitreal 1.25mg / 0.05ml bevacizumab injection was applied to the patients with one month intervals. Visual acuity (VA), central foveal thickness (CFT) and complications were recorded. The t-test was used to compare the data and P<0.05 was considered as statistically significant.

Results: The mean foveal thickness of the patients before injection was 548.0±227.8 μm, while it was 272.8±128.6 μm in the first month and 269.6±125.7 μm in the third month after injection. When compared with preoperative central foveal thickness, a decrease in the thickness of the central fovea was observed in the 1st and 3rd month after the treatment. All these reductions in CFT were statistically significant (P<0.05). The mean visual acuity of the patients before the injection was found as 0.72±0.45 logMAR (0.10–2.0) and 0.39±0.41 logMar (0.0–1.1) at the 1st month after injection and 0.41±0.38 logMar at the 3rd month (range: 0.0–1.3).

Conclusion: There was a statistically significant increase in best corrected visual acuity (BCVA) at the 1st and 3rd months after injection when compared with pre-injection values (P< 0.05).